Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 13.03 |
| Open | 13.21 |
| Bid | 13.33 x 4000 |
| Ask | 13.34 x 1400 |
| Day's Range | 13.19 - 13.38 |
| 52 Week Range | 12.77 - 16.39 |
| Volume | |
| Avg. Volume | 1,567,880 |
| Market Cap | 41.893B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 46.03 |
| EPS (TTM) | 0.29 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | 0.64 (4.78%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | 18.23 |
Business WireTakeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan & CAMBRIDGE, Mass., May 31, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP. The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for rAD
CNW GroupTakeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY® (maribavir) for the treatment for adults with a post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 With the LOI stage now complete, the provinces and territories may proceed in initiating their individual pro
Business WireTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
